Overall Survival

Final EMBARK Results Show 40% Lower Mortality With Enzalutamide Plus Leuprolide in High-Risk Recurrent Prostate Cancer

NEJM publication with ESMO presentation positions the regimen for stronger guidelines, with manageable safety tradeoffs.